1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors. - Coward, J; Lemech, C; Meniawy, T; Dupont, C D; Gonzalez, A M; Lim, M; Savitsky, D; Carini, M; Hu, S; Shebanova, O (Annals of Oncology, 2018)